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E3-6.7K is a small and hydrophobic membrane glycoprotein encoded by the E3 region of subgroup C
adenovirus. Recently, E3-6.7K has been shown to be required for the downregulation of tumor necrosis factor
(TNF)-related apoptosis-inducing ligand (TRAIL) receptors by the adenovirus E3/10.4K and E3/14.5K complex
of proteins. We demonstrate here that E3-6.7K has additional protective roles, independent of other virus
proteins. In transfected Jurkat T-cell lymphoma cells, E3-6.7K was found to maintain endoplasmic reticulum-
Ca2 homeostasis and inhibit the induction of apoptosis by thapsigargin. The presence of E3-6.7K also lead
to a reduction in the TNF-induced release of arachidonic acid from transfected U937 human histiocytic
lymphoma cells. In addition, E3-6.7K protected cells against apoptosis induced through Fas, TNF receptor,
and TRAIL receptors. Therefore, E3-6.7K confers a wide range of protective effects against both Ca2
flux-induced and death receptor-mediated apoptosis.
Adenovirus can lead to persistent infections of the eye, ear,
and respiratory and digestive tracts in humans (23). Neverthe-
less, during the early stages of adenovirus infection, events
related to cellular transformation and viral gene expression are
responsible for triggering apoptosis of the host cell. Primarily,
the expression of the adenoviral genes E1A and E4orf4
induces apoptosis in both a p53-dependent (59) and a p53-
independent manner (53, 91). E1A is also implicated in the
increased susceptibility of infected cells to death receptor-
induced apoptosis (15). Therefore, other virus proteins must
preserve the integrity of the cell and allow viral replication to
be completed. Adenovirus antiapoptotic proteins include the
Bcl-2 homologue E1B 19K (8, 32) and the inhibitors of p53-
induced apoptosis E1B 55K (104) and E4orf6 (20). Meanwhile,
the E3 region encodes inhibitors of death receptor-induced
apoptosis, such as the 6.7K (6) and 14.7K (27, 54) proteins and
the complex formed by the 10.4K and 14.5K proteins, also
known as receptor internalization and degradation (RID) pro-
teins  and , respectively (6, 22, 83, 93).
Most viral survival factors can be classified according to
which host survival protein they mimic. For example, there are
viral Bcl-2-like proteins, such as BHRF1 (33) and A179L (1),
and others that mimic the Fadd-like interleukin-converting
enzyme-inhibitory protein, such as K13, BORFE2, and MC159
(92). There are also homologues of the cellular inhibitor of
apoptosis proteins (17) and serpin homologues (19), both of
which inhibit caspases and/or caspase activation. Ultimately,
there are viral proteins that mimic death receptors and prevent
their ligation, like MT-2 (79), SFV-T2 (85), CrmB (37), CrmC,
and CrmD (58).
Notable exceptions to this classification are antiapoptotic
viral proteins for which no cellular homologue or mode of
action has been identified. Interestingly, some of these proteins
are localized in the endoplasmic reticulum (ER). For instance,
a subset of the M-T2 protein, the myxoma virus homologue of
the tumor necrosis factor (TNF) receptor, is ER retained, yet
it is able to block apoptosis (80). MT-4, another ER-localized
myxoma virus protein, has also been shown to prevent apopto-
sis, through an unknown mechanism (4). Similar to M-T2,
UL144 is an intracellular membrane protein homologous to
the TNF receptor superfamily of proteins (5). Even ER-local-
ized cellular proteins, shown to have an effect on apoptosis,
have a poorly defined mechanism. Some of these cellular fac-
tors are protective, such as DAD1 (also known as Ost2p) (88),
PDI (90), Grp94 (56), calreticulin (57), and Grp78 (87), while
others are proapoptotic, such as BAP31 (70) and mutant forms
of PS-1 (45) and PS-2 (40), associated with familial Alzhei-
mer’s disease.
The adenovirus type 2 (Ad2) E3-6.7K protein is localized
primarily in the ER, as evidenced by cellular immunofluores-
cence staining and by the presence of high-mannose N-linked
glycan modifications in the mature protein (103). There is
evidence that a small subset of this protein is found on the
plasma membrane where it associates with RID  and allows
the RID complex to downregulate the DR4 and DR5 TNF-
related apoptosis-inducing ligand (TRAIL) receptors (6).
However, a recent study using different experimental condi-
tions suggests that E3-6.7K is not required for the downregu-
lation of DR4 by RID (95), yet it may still be required by RID
in downregulating DR5. The RID complex also downregulates
Fas (6, 22, 83, 93) and epidermal growth factor receptor (94)
and prevents TNF-induced apoptosis (28), arachidonic acid
release (48), and translocation of cytosolic phospholipase A2
(cPLA2) to the membrane (18). E3-6.7K, however, was not
shown to be required for any of the latter effects but may play
a role in augmenting RID function. We focused our studies on
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examining E3-6.7K in the absence of other viral factors, in
order to explore whether it has an independent role in apo-
ptosis.
Our findings indicated that the adenovirus E3-6.7K protein
maintained Ca2 homeostasis in transfected cells since its ex-
pression buffered the Ca2 flux generated in response to thap-
sigargin, an inhibitor of the ER-associated Ca2 ATPase. This
led to the resistance of E3-6.7K-transfected cells to thapsigar-
gin-induced apoptosis. The newly observed effect of E3-6.7K
was independent of the RID complex and cannot be explained
by its previously proposed role in downregulating DR4 and
DR5. In addition, TNF-, TRAIL-, and Fas ligand (FasL)-
induced apoptosis and TNF-induced release of arachidonic
acid were significantly reduced in cells expressing E3-6.7K. We
speculate that E3-6.7K may offer the virus a powerful and
broad survival mechanism by preventing death receptor- or
Ca2 efflux-induced apoptosis and by reducing the release of
inflammatory mediators.
MATERIALS AND METHODS
Plasmid constructs. To amplify the cDNA for E3-6.7K, the forward primer
ACCACCATGAGCAATTCAAGTAACTC, the reverse primer CCTTATCTT
GGATGTTGCCCCCAG, and template DNA consisting of the EcoRI D frag-
ment of the E3 region of Ad2 (a kind gift from W. S. M. Wold) were used. The
PCR product was cloned into the bovine papillomavirus-based episomal expres-
sion vector pBCMGSneo for transfection into U937 cells. The cDNA was also
subcloned into pIRESpuro2 (Clontech) for transfection into Jurkat cells. Both
strands of the inserted E3-6.7K coding region were sequenced by LoneStar Labs
(Austin, Tex.) to ensure accuracy.
Generation of U937 and Jurkat cell lines stably expressing E3-6. 7K. U937
human histiocytic lymphoma (89) and Jurkat E6-1 T-cell lymphoma (101) cells,
obtained from the American Type Culture Collection, were maintained in RPMI
1640 containing 10% fetal calf serum, 2 mM L-glutamine, 10 mM HEPES, 100 U
of penicillin per ml, and 100 g of streptomycin per ml in an atmosphere of 5%
CO2 and 100% humidity.
U937 cells were transfected with the vector pBCMGSneo (44) alone or with
pBCMGSneo carrying E3-6.7K by using the DMRIE-C cationic lipid reagent
(Life Technologies) and following the manufacturer’s protocol. Briefly, 4 g of
DNA was mixed and incubated for 30 min with 0.5 ml of Opti-MEM medium
(Life Technologies) and 12 l of DMRIE-C. The liposome-DNA mix was then
mixed and incubated with 0.5 ml of 5  105 cells in Opti-MEM medium for an
additional 4 h. Stably transfected cells were selected with 1 mg of G-418 sulfate
per ml 48 h later.
Jurkat cells were transfected by electroporation. Cells (2.5  107) were washed
twice in Opti-MEM medium, mixed with 20 g of the appropriate plasmid, and
electroporated with a Bio-Rad Electroporator at 250 V and 950 F. Transfected
cells were selected in medium containing 0.5 g of puromycin per ml. The
pIRESpuro2 vector (Clontech) carries the encephalomyocarditis virus internal
ribosome entry site (IRES), allowing cocistronic expression of E3-6.7K and the
puromycin resistance gene.
Several subclones of the transfected cell lines were generated by serial dilution
and examined for expression of E3-6.7K transcript by Northern blotting. The
expression of E3-6.7K was very similar in all the clones examined. However, all
the G-418- and puromycin-resistant U937 and Jurkat cells that survived the
selection procedure were pooled and used in our experiments, in order to avoid
clonal variation.
Ratiometric intracellular [Ca2] determination. Jurkat-neo and Jurkat-6.7K
cells were washed and resuspended at a concentration of 107 cells/ml in Opti-
MEM (Life Technologies). Aliquots of 100 l of the cell suspension were incu-
bated for 90 min at 37°C with 6.0 g of Indo-1 AM ester per ml. Prior to analysis,
1.9 ml of Opti-MEM was added to the cell suspension. Intracellular Ca2 levels
were measured with the ratiometric Ca2 indicator Indo-1; its emission maxi-
mum shifts from 485 nm in Ca2-free medium to 400 nm when the dye is
saturated with Ca2. The ratio of the emission signals at 405 nm and 485 nm
represents the ratio of Ca2-bound to Ca2-free Indo-1. The kinetic analysis
examined approximately 2  104 cells/min with a FACS-Vantage sorter equipped
with an UV laser and appropriate filters for the 405- and 485-nm wavelengths.
After the establishment of a stable baseline for the first 5 min, the cells were
stimulated with 5 nM thapsigargin and monitored for another 20 min.
Arachidonic acid release assays. U937-neo and U937-6.7K cells were grown at
low density in 10% HyClone fetal calf serum, RPMI 1640, 2 mM L-glutamine,
and 10 mM HEPES for several days and then harvested and washed twice in
phosphate-buffered saline (PBS)–1% bovine serum albumin. Approximately 5 
106 cells (5  105 cells/ml) were labeled for 20 h in medium supplemented with
0.4 Ci of [3H]arachidonic acid [5,6,8,9,11,12,14,15-3H(N)] (0.1 mCi/ml stock;
New England Nuclear) per ml. Cells were washed twice in RPMI 1640–0.2%
bovine serum albumin and incubated for 1 h in wash medium to minimize the
spontaneous release of [3H]arachidonic acid. Then 2  105 cells were stimulated
with either medium alone, 90 ng of TNF (2,000 U/ml) (Boehringer Mannheim)
per ml, 2 g of cycloheximide (CHX) per ml, or a combination of 90 ng of TNF
and 2 g of CHX per ml for 20 h. The cellular supernatant from three indepen-
dent experimental samples was mixed with scintillation fluid and counted to
determine the amount of released radioactivity. For each cell line, three samples
were lysed in Tris-buffered saline (50 mM Tris [pH 7.5], 150 mM NaCl [TBS])
containing 2% CHAPS {3-[(3-cholamidopropyl)-dimethylammonio]-1-propane-
sulfonate}, and the lysate was used to determine the total amount (in counts per
minute) of incorporated [3H]arachidonic acid. The amount of [3H]arachidonic
acid released in experimental samples was expressed as a percentage of the total
incorporated [3H]arachidonic acid.
Thapsigargin-induced apoptosis assays in transfected Jurkat cells. Following
induction of apoptosis in Jurkat-neo and Jurkat-6.7K cells with 1 or 10 M
thapsigargin for 24 h, we used the DNA-intercalating dye YO-PRO-1 (Molecular
Probes) as an assay of membrane permeability changes. Cells were harvested,
washed in PBS, and resuspended at a concentration of 106 cells/ml. Following
staining with 0.1 M YO-PRO-1 and 1 g of propidium iodide (PI) per ml, the
cells were analyzed by flow cytometry with FL1530 nm- and FL2575 nm-
compensated emission readings on a FACScan (Becton Dickson). Viable, apo-
ptotic cells showed green fluorescence, necrotic cells showed red and green
fluorescence, and live, nonapoptotic cells showed very little fluorescence. The
apoptotic index (AI) excluded the necrotic cell population and was calculated as
(number of viable apoptotic cells/total number of viable cells)  100.
Death receptor-induced apoptosis assays in transfected U937 and Jurkat
cells. Fluorescein isothiocyanate (FITC)-conjugated annexin V (Pharmingen)
was used to determine the binding of annexin V to externalized phosphatidyl
serine. The protocol was based on the manufacturer’s annexin V-FITC staining
protocol. For each sample, 5  106 U937-neo or U937-6.7K cells were harvested,
washed twice in PBS, and treated for 7 h with medium alone, 100 ng of TNF per
ml, 10 g of CHX per ml, or a combination of 100 ng of TNF and 10 g of CHX
per ml. The cells were stained with 5 l of annexin V-FITC in a mixture
containing 10 mM HEPES–NaOH (pH 7.4), 140 mM NaCl, and 2.5 mM CaCl2
and analyzed with a fluorescence-activated cell sorter (FACS). Viable cells were
gated based on their side scatter characteristics, and apoptotic cells were distin-
guished from nonapoptotic cells based on their green fluorescence.
Alternatively, in the experiments examining FasL and TRAIL-induced apo-
ptosis, 5  106 Jurkat-6.7K or Jurkat–neo cells each were harvested, washed
twice in PBS, and treated with agonist for 12 h. The treatment consisted of either
1 g of DX2 (anti-human Fas monoclonal antibody) (Pharmingen) per ml and 2
g of goat anti-mouse secondary antibody per ml or a recombinant fusion
protein containing the extracellular domain of TRAIL (10 ng/ml; Upstate Bio-
tech.) and a potentiating reagent (5 g/ml; Upstate Biotechnology) which con-
sists of a monoclonal antibody against the tag present in purified TRAIL. In
these experiments, we used both the annexin V–Alexa-488 and the previously
described YO-PRO-1 apoptosis assays (Molecular Probes). Like annexin-FITC,
annexin V–Alexa-488 (Molecular Probes) labels cells that externalize phosphati-
dyl serine. The same staining protocol was followed, with the exception that a
highly fluorescent non-cell-permeating DNA-intercalating dye, 50 M Cy-
toxGreen (Molecular Probes), was used to label necrotic cells. We examined the
green fluorescence of stained cells with a FACS (Becton Dickinson). Viable,
nonapoptotic cells showed little or no green fluorescence, while viable, apoptotic
cells showed intermediate green fluorescence. Necrotic cells, on the other hand,
showed 10 times greater fluorescence due to CytoxGreen staining than the
apoptotic cells labeled with annexin V–Alexa-488 alone.
Activation of caspase-3 and cleavage of PARP by Western blotting. To analyze
the cleavage of poly(ADP-ribose) polymerase (PARP), cell lysate equivalent to
105 cells was denatured in sodium dodecyl sulfate (SDS) sample buffer (0.1 M
Tris [pH 6.8], 24% glycerol, 8% SDS, 0.2 M dithiothreitol, 0.02% bromophenol
blue). The protein concentration was determined with a bicinchoninic acid assay
kit (Pierce). Equivalent amounts of protein from each sample were resolved on
a 10% glycine–SDS–polyacrylamide gel electrophoresis (PAGE) Laemmli gel
system, blotted with the Towbin vertical-transfer wet system onto a 0.45-m-
VOL. 76, 2002 ADENOVIRUS E3-6.7K HAS A BROAD ANTIAPOPTOTIC EFFECT 1579
 on July 18, 2014 by U
niversity of K
ansas
http://jvi.asm
.org/
D
ow
nloaded from
 
pore-size Immobilon-P polyvinylidene difluoride (PVDF) membrane (Milli-
pore), and incubated with anti-PARP mouse monoclonal antibody (1:5,000 di-
lution; Pharmingen). After four washes in TBS containing 0.1% Tween 20
detergent (TBS-T), the blot was incubated with horseradish peroxidase-conju-
gated goat anti-mouse antiserum (1:50,000 dilution) and visualized by chemilu-
minescence with a SuperSignal West Pico kit (Pierce Chemical). Alternatively, to
detect caspase-3 activation, the cell lysate was resolved on a 10% T, 3% C
Tricine-SDS-PAGE gel without spacer, blotted with a Towbin vertical-transfer
wet system on a 0.2-m-pore-size Immobilon-P PVDF membrane (Millipore),
and incubated with anti-caspase-3 rabbit polyclonal antibody (1:5,000 dilution;
Pharmingen). After four washes in TBS-T, the blot was incubated with horse-
radish peroxidase-conjugated goat anti-rabbit antiserum (1:50,000 dilution) and
visualized by chemiluminescence with a SuperSignal West Pico kit (Pierce Chem-
ical).
RESULTS
The expression of E3-6.7K is sufficient to protect transfected
cells against death receptor and thapsigargin-induced apopto-
sis. It has been previously shown that E3-6.7K cooperates with
RID  and  to downregulate the level of TRAIL receptors 1
and 2 from the surfaces of cells (6). While this identifies a role
for the subset of the E3-6.7K protein expressed at the cell
surface and possibly the endosomal compartment, it does not
directly indicate a role for the large subset of the protein which
is retained in the early secretory compartment. We began our
studies by examining the effect of E3-6.7K on death receptor-
induced apoptosis in transfected cells, in the absence of other
viral proteins.
We chose to study the effects of E3-6.7K in cells of lymphoid
and monocytic origin. Both cell types have been implicated as
a possible reservoir for persistent adenovirus infections in vivo
(2, 3, 13, 35, 84, 99). Immune evasion and the establishment of
viral persistence may be more appropriately studied in cells
resembling the in vivo reservoir of adenovirus. Subgroup C
Ad5 can establish persistent infection in the human monocytic
cell line U937, which maintains large copy numbers of uninte-
grated viral genomes following infection (13). Infected cells
continue to grow and produce minute amounts of mature virus
a year after infection. The Ad5-infected U937 cells have been
proposed to provide a model of persistent adenovirus infection
in humans. The human Jurkat T-cell line, on the other hand,
has been used to study the efficacy of the immunoevasive
protein E3/19K in downregulating major histocompatibility
complex class I in lymphoid cells (47). We examined the re-
sponses of E3-6.7K-transfected Jurkat or U937 cells to medi-
ators of apoptosis and inflammation.
We transfected E3-6.7K cDNA amplified by PCR from a
plasmid bearing the E3 region into the TNF-sensitive U937
human histiocytic lymphoma cell line. We established a stable
population of U937 cells transfected with the episomal vector
pBCMGSneo containing the cDNA for E3-6.7K (U937-6.7K)
and another population transfected with vector alone (U937-
neo). All surviving neomycin-resistant cells (in excess of 103
clones) were pooled and used in the following experiments to
avoid the clonal variation known to arise in U937 cells. Ex-
pression of E3-6.7K was analyzed by Northern blotting and by
immunoprecipitation. We confirmed that the E3-6.7K protein
was properly synthesized by immunoprecipitating it with a
polyclonal rabbit antiserum raised against an E3-6.7K C-ter-
minus-derived peptide and examined it by SDS-PAGE (results
not shown).
We assayed the response of U937-neo and U937-6.7K cells
to TNF-induced apoptosis by measuring the externalization of
phosphatidyl serine by apoptotic cells (61) stained with an-
nexin V-FITC. The presence of E3-6.7K yielded a 2.2-fold
reduction in the proportion of apoptotic cells in U937-6.7K
compared to U937-neo, following stimulation with TNF (Fig.
1). The U937-6.7K cells showed a 2.8-fold reduction in apo-
ptosis compared to U937-neo cells following augmented stim-
ulation with a combination of TNF and CHX, a protein syn-
thesis inhibitor synergistic with TNF. The presence of E3-6.7K
significantly decreased the apoptotic response in U937 cells
upon stimulation with TNF or a combination of TNF and
CHX.
FIG. 1. E3-6.7K protects against apoptosis induced by TNF in U937 cells. U937-neo (a to d) and U937-6.7K (e to h) cells were stimulated for
7 h with medium alone, 100 ng of TNF per ml, 10 g of CHX per ml, or a combination of 100 ng of TNF and 10 g of CHX per ml. For each
cell population, a sample treatment was stained with annexin V-FITC and analyzed with a FACS. A second sample was analyzed with a FACS in
the absence of annexin V-FITC in order to determine the background fluorescence, which corresponds to the fluorescence associated with the
annexin V-negative cell population from each sample. The AI was calculated as (number of annexin V-positive viable cells/total number of viable
cells)  100. The results are representative of three repeat experiments.
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The pronounced effect of E3-6.7K on TNF-induced apopto-
sis hinted at the possibility that apoptosis induced by other
death receptors may also be affected. Both Fas and TRAIL
receptors DR4 and DR5 are similar to TNF receptor 1 in the
sense that they contain death effector domains. The effect of
E3-6.7K on apoptosis induced through Fas and TRAIL recep-
tors was examined in transfected Jurkat E6-1 T-cell leukemia
cells. Jurkat cells were transfected with the cDNA for E3-6.7K
expressed by pIRESpuro2 (Clontech), which contains the en-
cephalomyocarditis virus IRES, allowing the cocistronic ex-
pression of E3-6.7K and the puromycin-N-acetyl-transferase
gene. Selection with puromycin acted directly on the expres-
sion cassette coding for E3-6.7K. The resistant population of
cells was pooled and used in our experiments.
We found that Jurkat cells stably transfected with E3-6.7K
(Jurkat-6.7K) cells were less sensitive to apoptosis induced
through Fas (Fig. 2) or TRAIL (Fig. 3) receptors than Jurkat
cells transfected with vector alone (Jurkat-neo) cells. Follow-
ing stimulation with FasL or TRAIL, the apoptotic response
was assayed by two independent methods. In addition to an-
nexin V labeling of externalized phosphatidyl serine, we also
measured the exclusion of the dye YO-PRO-1 by viable, non-
apoptotic cells. In both assays we used a viability dye to stain
the necrotic and late-apoptotic cell population, commonly ex-
cluded from the analysis of induction of apoptosis. Analysis of
the apoptotic response was performed in accordance with
manufacturer’s instructions and in accordance with published
methods used in similar studies (11, 42, 78, 81, 97). Both assays
demonstrated that E3-6.7K was effective in reducing TRAIL-
and FasL-induced apoptosis in Jurkat cells. It is important to
note that the antiapoptotic effect of E3-6.7K against TNF- and
TRAIL-induced apoptosis was more pronounced than that
against FasL-induced apoptosis, as observed by measuring the
externalization of phosphatidyl serine (Fig. 1, 2A, and 3A).
In addition to death receptor-induced apoptosis, E3-6.7K con-
fers a similar degree of protection against thapsigargin, a media-
tor of apoptosis that acts intracellularly by mimicking a sustained
Ca2 flux (43). Thapsigargin, a sesquiterpene lactone, isolated
from the umbelliferous plant Thapsa garganica, selectively in-
hibits the ER Ca2-ATPase that directs Ca2 uptake into the
ER. This agent has been shown to induce apoptosis in Jurkat cells at
high doses (86). Following induction of apoptosis in both Jur-
kat-6.7K and in control Jurkat-neo cells, we measured the
increase in membrane permeability of apoptotic cells to the DNA-
intercalating dye YO-PRO-1 (38). We found that E3-6.7K pre-
vented thapsigargin-induced apoptosis, which suggests an
effect on ER Ca2 homeostasis (Fig 4A). The effects of E3-
6.7K on TRAIL- and 10 M thapsigargin-induced apoptosis
were comparable, resulting in dramatic improvement in the survival
of transfected cells, as assayed by measuring the increase in
membrane permeability during apoptosis (Fig. 3B and 4A ).
Efflux of Ca2 from the ER in response to thapsigargin is
reduced in the presence of E3-6.7K. Thapsigargin induces ap-
optosis through the increase in cytosolic Ca2 followed by the
activation of mediators of apoptosis. To better understand the
mechanism of action of E3-6.7K, we assayed whether it has any
direct effect on the thapsigargin-induced rise in cytosolic Ca2
or whether it simply acts downstream of the Ca2 flux by
affecting apoptotic mediators. Both Jurkat-neo and Jurkat-
6.7K cells were loaded with the Ca2-sensitive fluorophore
Indo-1. Following treatment with thapsigargin, the Ca2 flux
was assayed by FACS and represented using a ratiometric
value of the amount of Ca2-bound Indo-1 to the amount of
Ca2-free Indo-1 per cell. The graph shown in Fig. 4B repre-
sents the kinetic analysis of the mean of the ratiometric values
of approximately 20,000 cells/min.
FIG. 2. E3-6.7K protects against apoptosis induced by Fas in Jur-
kat-neo and Jurkat-6.7K cells. To study Fas-induced apoptosis, cells
were stimulated for 12 h with 1 g of the anti-human Fas monoclonal
antibody DX2 (Pharmingen) per ml and 2 g of goat anti-mouse
polyclonal antibody per ml. (A) Apoptotic cells were stained with
annexin V–Alexa-488, indicating externalization of phosphatidyl
serine; AI  (number of annexin V-positive, CytoxGreen-negative
cells/total number of CytoxGreen negative cells)  100. The V sector
indicates the nonapoptotic, viable cell population, the A sector indi-
cates the apoptotic, viable cell population, and the N sector indicates
the necrotic cell population. (B) Alternatively, cells were stained with
YO-PRO-1, indicating an increase in membrane permeability; AI 
(number of YO-PRO-1-positive, PI-negative cells/total number of PI-
negative cells)  100. The lower left quadrant is the nonapoptotic,
viable cell population, the lower right quadrant (A) represents the
apoptotic, viable cell population, and the upper right quadrant
(N) represents the necrotic cell population.
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Thapsigargin-induced Ca2 flux in Jurkat-neo cells resulted
in an 80% increase in the level of intracellular calcium. In
Jurkat-6.7K cells, however, the observed increase was re-
stricted to 34% (Fig. 4B). The presence of E3-6.7K reduced
the efflux of Ca2 in response to thapsigargin. The observed
decrease in Ca2 homeostasis correlates with the protective
role conferred by E3-6.7K against thapsigargin-induced apo-
ptosis. Both apoptosis and Ca2 flux assays were conducted in
FIG. 3. E3-6.7K protects against apoptosis induced by TRAIL in
Jurkat-neo and Jurkat-6.7K cells. To study TRAIL-induced apoptosis,
cells were stimulated for 12 h with 10 ng of a recombinant fusion
protein containing the extracellular domain of TRAIL (Upstate Bio-
technology) per ml and a potentiating reagent (5 g/ml; Upstate Bio-
technology), which consists of a monoclonal antibody against the tag
present in purified TRAIL. (A) The apoptotic cells were stained with
annexin V–Alexa-488, indicating externalization of phosphatidyl
serine; AI  (number of annexin V-positive, CytoxGreen-negative
cells/total number of CytoxGreen-negative cells)  100. The V sector
indicates the nonapoptotic, viable cell population, the A sector indi-
cates the apoptotic, viable cell population, and the N sector indicates
the necrotic cell population. (B) Alternatively, cells were stained with
YO-PRO-1, indicating an increase in membrane permeability; AI 
(number of YO-PRO-1-positive, PI-negative cells/total number of PI-
negative cells)  100. The lower left quadrant is the nonapoptotic,
viable cell population, the lower right quadrant (A) represents the
apoptotic, viable cell population, and the upper right quadrant
(N) represents the necrotic cell population.
FIG. 4. The presence of E3-6.7K results in the reduction of the
thapsigargin-induced Ca2 flux and apoptosis. (A) Effect of E3-6.7K
on thapsigargin-induced apoptosis in transfected Jurkat cells. Jurkat-
6.7K and Jurkat-neo cells were stimulated with medium containing 1%
dimethyl sulfoxide (top),or 1 or 10 M thapsigargin (TG) for 24 h, and
then they were stained with YO-PRO-1 to examine the increase in the
membrane permeability of apoptotic cells. The AI excluded the ne-
crotic cell population and was calculated as (number of YO-PRO-1-
positive, PI-negative apoptotic cells/total number of PI-negative, viable
cells)  100. The A region represents the apoptotic, viable population,
and V represents the nonapoptotic, viable population; AI  A/(AV).
The experiment was repeated with similar results: 23.2%  1.4% and
47.8%  4.7% for Jurkat-neo cells stimulated with 1 and 10 M TG,
respectively, and 10.3%  1.3% and 21.9%  6.6% for Jurkat-6.7K
cells stimulated with 1 and 10 M TG, respectively (P 	 0.05). (B) Ki-
netic analysis of the effect of E3-6.7K on the release of Ca2 from the
ER in response to TG. Jurkat-6.7K and Jurkat-neo cells were loaded
for 90 min at 37°C with 0.5 M Indo-1 AM ester and examined on a
UV-equipped FACS-Vantage flow cytometer (Becton Dickinson) for 5
min to establish the baseline fluorescence, equivalent to the resting
level of intracellular calcium. At 5 min, cells were treated with 5 nM
TG and analyzed for 25 min for a total of 5  105 events. The
experiment was repeated three times with similar results.
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media containing extracellular Ca2, which is essential for the
induction of apoptosis in Jurkat cells by thapsigargin (31). As
a result, the initial ER Ca2 flux is amplified by capacitative
Ca2 entry through Ca2 release-activated Ca2 channels.
The presence of E3-6. 7K delays TNF-induced activation of
caspase-3 and cleavage of PARP. Given the protective role of
E3-6.7K against both death receptor- and Ca2-induced apo-
ptosis, we examined its effect on the so-called “executioner”
phase of apoptosis. More specifically, we assayed its effect on
the TNF-induced cleavage of procaspase-3 and of the DNA
repair enzyme PARP (Fig. 5). The 17- and 11-kDa proteolytic
products of procaspase-3 are subunits of the heterodimeric,
active form of caspase-3. The appearance of the active forms of
caspase-3 was significantly delayed in U937-6.7K versus U937-
neo cells (Fig. 5A). In addition, there was a significant reduc-
tion in the amount of active caspase-3 in U937-6.7K cells
versus U937-neo cells. The 85-kDa inactive form of PARP
appeared in both U937-neo and U937-6.7K cell lines at 2 h
after stimulation with TNF-CHX (Fig. 5B). There was, how-
ever, a noticeable difference with regard to the kinetics of
PARP inactivation: the amount of inactive PARP present in
the U937-6.7K cells was considerably reduced compared to
that in U937-neo cells. Therefore, the presence of E3-6.7K
delayed and reduced the activation of caspase-3 and inhibited
PARP inactivation during TNF-induced apoptosis.
TNF-mediated arachidonic acid release is reduced in the
presence of E3-6. 7K. As E3-6.7K affects Ca2 homeostasis in
transfected cells, it became imperative to test its effect on the
TNF-induced release of arachidonic acid, which is a Ca2-
dependent process. One possible candidate for the TNF-induc-
ible release of arachidonic acid is the calcium-dependent
cPLA2, which is activated by the dual signal of Ca
2 release
from the ER stores and phosphorylation (68). In the presence
of a sustained Ca2 flux, cPLA2 translocates preferentially to
the ER and nuclear envelope (72, 77). There, it releases ara-
chidonic acid from the sn-2 position of various phospholipids,
leading to the formation of eicosanoids, such as leukotrienes
and prostaglandins, important mediators of inflammation.
We found that in the presence of E3-6.7K there was a re-
duction in the release of [3H]arachidonic acid from U937-6.7K
cells by 50% compared to that from U937-neo cells following
stimulation with TNF (Fig. 6). When the stimulus was in-
creased by the addition of TNF and CHX, U937-6.7K cells
released 60% less [3H]arachidonic acid than U937-neo cells
(Fig. 6). This effect can be explained by the fact that E3-6.7K
affects Ca2 homeostasis, which indirectly affects the activity of
cPLA2. Our assay of [
3H]arachidonic acid release was con-
ducted for periods ranging from 12 to 48 h after stimulation
(results not shown). The amount of soluble [3H]arachidonic
acid is an equilibrium determined by cycles of deacylation and
reacylation. We found that in our system, the equilibrium fa-
vored deacylation of incorporated [3H]arachidonic acid for the
first 24 h, reaching the peak of release of [3H]arachidonic acid
FIG. 5. Effect of E3-6.7K on the induction of procaspase-3 process-
ing and PARP cleavage during TNF-induced apoptosis in vivo. Cell
extracts were obtained from U937-neo and U937-6.7K cells that had
been treated with 10 ng of TNF and 0.5 g of CHX per ml for various
lengths of time. Lysates containing equivalent amounts of protein
based on the bicinchoninic acid (Pierce) protein concentration assay
were loaded in each lane. After electrophoresis and transfer to PVDF
membranes, blots were incubated with anti-caspase-3 rabbit antiserum
that recognizes the 17- and 11-kDa subunits of the active, processed
protein (A) and anti-PARP mouse monoclonal antibody that recog-
nizes both the active 116-kDa and inactive 85-kDa forms of the protein
(B). The blots were developed with a secondary antibody and visual-
ized by chemiluminescence (Pierce Chemical). Similar results were
obtained in two repeat experiments.
FIG. 6. Analysis of the effect of E3-6.7K on the inducible release of
radiolabeled arachidonic acid. U937-neo and U937-6.7K cells were
stimulated with medium alone, 90 ng of TNF per ml, 2 g of CHX per
ml, or a combination of 90 ng of TNF and 2 g of CHX per ml. After
20 h, the amount (in counts per minute) of [3H]arachidonic acid
released in the medium was expressed as a percentage of the total
incorporated [3H]arachidonic acid. The assay was set up in triplicate;
however, due to their relatively small values, the standard deviations of
the values for the samples from U937-6.7K cells treated with medium
alone (6.72%  0.037%) and U937-6.7K treated with CHX (5.74% 
0.027%) are difficult to observe on this graph. These results are rep-
resentative of six repeat experiments.
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at 20 h poststimulation. The release of incorporated [3H]ara-
chidonic acid over the next 24 h was minimal as intracellular
stores of [3H]arachidonic acid became depleted. As a result, we
studied the effect of E3-6.7K at 20 h poststimulation. The effect
of E3-6.7K on the release of arachidonic acid is consistent with
its protective role against apoptosis and correlates with its
effect on Ca2 homeostasis.
DISCUSSION
Adenovirus has been isolated from adenoids and tonsils of
patients with acute respiratory diseases. A large percentage of
these tissues are composed of lymphoid cells. Adenovirus
DNA and infectious particles has been detected in cells of
lymphoid origin, which may form a reservoir for persistent
adenovirus infection in humans (2, 3, 13, 35, 84, 99). In spite of
this, adenovirus has been propagated and studied in cells of
nonlymphoid origin, such as HeLa, A549, and HEK-293 cells,
because infection and replication of adenovirus in lymphoid
cells are not as efficient as those in nonlymphoid cells. Lym-
phoid-derived cell lines and peripheral blood lymphocytes are
not permissive to Ad2 infection (36) and can be infected by
adenovirus only at a high multiplicity of infection (84, 96).
Cultured lymphocytes isolated from adenoids were found to
support viral replication very poorly (96). This may be due, in
part, to the fact that lymphocytes appear to lack the coxsack-
ievirus and adenovirus receptor protein (76). Nevertheless, it is
possible that the delayed kinetics of infection and replication
of adenovirus in lymphoid cells are related to the establish-
ment of viral persistence in a small fraction of lymphoid cells
(52). As a result, in vitro models of persistent infection of
lymphoid and monocytic cells have been established in tissue
culture of Burkitt’s lymphoma cell line, Raji, the acute lym-
phoblastic-T-cell-leukemia-derived cell line MOLT-3 (84, 96),
and the histiocytic lymphoma cell line U937 (13).
The promoter that controls the E3 region is active in cells of
lymphoid origin in the absence of E1A (102) and is responsive
to TNF (16). It is possible that the role of the E3 region
proteins in lymphoid cells is to aid in the establishment of
persistent infections. Our studies examine the role of E3-6.7K
in protecting cells of lymphoid and monocytic origin from
apoptosis, with implications for the persistent viral infection
seen in vivo in tonsillar or adenoidal lymphoid cells or in cells
of monocytic origin. The effect of E3-6.7K on apoptosis in
these cells was examined by transfection of the cDNA coding
for E3-6.7K and creation of stable cell lines. The alternate
approach would have been to study the response of lymphoid
cells to apoptosis following infection of these cells with wild-
type virus or virus with a deletion of E3-6.7K. We favored the
single-gene-transfection approach for a number of reasons.
Firstly, infection of lymphoid cells with subgroup C virus is
extremely inefficient (84, 96), though there is a report of pro-
ductive infection of Jurkat cells by Ad5 (51). Secondly, the only
published deletion virus considered to have a single deletion in
the E3-6.7K gene, dl739, was recently observed to express
reduced levels of RID  protein (W. S. M. Wold, personal
communication). This may be due to a secondary deletion but
is more likely due to the fact that any deletion in the very
complex transcription unit, E3, has the potential to alter the
splicing pattern and 3'-end formation of E3 transcripts. Such
cis-acting sequences have been found to lead to the aberrant
expression of genes not directly affected by the deletion (7, 9).
This therefore precludes the assumption that viruses with de-
letions of various E3 proteins have a normal pattern of expres-
sion of the remaining genes and affects the conclusions derived
from studies that employ such viruses.
Our results indicate that the E3-6.7K protein acted in the
absence of other adenovirus proteins to protect transfected
cells against TNF-, FasL-, and TRAIL-induced apoptosis and
against TNF-induced arachidonic acid release. More impor-
tantly, thapsigargin-induced Ca2 efflux and apoptosis were
dramatically reduced in the presence of E3-6.7K, which sug-
gests a possible effect of E3-6.7K on events that regulate Ca2
homeostasis. The three proteins coded by the E3 region, E3/
10.4K, E3/14.5K, and E3/14.7K, that prevent death receptor-
induced apoptosis have also been shown to prevent the release
of arachidonic acid following stimulation with TNF (48). Sim-
ilarly, E3-6.7K is effective in reducing the release of arachi-
donic acid. This newest addition to the E3 region proteins that
prevent both TNF-induced apoptosis and release of inflamma-
tory mediators reflects the importance of TNF and inflamma-
tion in the immune responses against adenovirus (21, 25).
The effect of E3-6.7K on TRAIL- or TNF-induced apoptosis
was comparable with its effect on thapsigargin-induced apo-
ptosis. This suggests that its effect on death receptor-induced
apoptosis, in the absence of RID  and , could in fact be
related to its effect on downstream events such as Ca2 release.
Currently, the role of Ca2 efflux from the ER during death
receptor-induced apoptosis is not very well understood. Some
studies describe an effect of Ca2 efflux on the apoptotic re-
sponse of cells to FasL (41) or TNF (46), while others disagree
(62). Still other studies attribute a role to Ca2 efflux in the late
and not early events following FasL-induced apoptosis (82).
Through the discovery of proteins that specifically affect Ca2
release, through well-defined mechanisms, it will be possible to
explore the role of Ca2 flux in death receptor-induced apo-
ptosis.
A previous study indicated that E3-6.7K is required by RID
 and  to reduce the surface level of TRAIL R1 and R2 and
prevent TRAIL-induced apoptosis (6). Interestingly, we noted
that many of the studies that examined the effect of RID  and
 made use of viral deletion mutants that were deficient in
RID  and  or both but retained the expression of E3-6.7K.
It is then plausible that E3-6.7K acts to augment the effects of
RID  and  in death receptor-induced apoptosis by acting
both alone and in combination with them. We propose, there-
fore, that E3-6.7K is an antiapoptotic protein with two possible
mechanisms. First, as previously shown, cooperating with other
viral proteins E3-6.7K results in the downregulation of TRAIL
receptors. Secondly, E3-6.7K acts alone to prevent apoptosis
against a variety of death receptors as well as intracellular
mediators of apoptosis. Its effect, in the absence of other viral
proteins, appears to involve the maintenance of cytosolic Ca2
homeostasis.
It is common for viral proteins to have more than one mech-
anism or function, a reflection, possibly, of the large number of
functions that need to be performed by a successful virus.
Some viral antiapoptotic proteins can use two distinct mecha-
nisms to achieve their goal, as previously described for the
TNF receptor homologue M-T2 (80) coded by myxoma virus.
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In addition, there are also examples of viral antiapoptotic pro-
teins that have both cooperative means, with other viral pro-
teins, and independent ones to achieve similar goals. For ex-
ample, adenovirus E4orf4 can act both independently and in
combination with E1A to induce apoptosis (53, 60), while
E4orf6 and E1B55K have both independent and cooperative
means to prevent it (20, 34).
Other viral and cellular proteins, such as p35 and the neu-
ronal apoptosis-inhibitory protein, have also been shown to
prevent thapsigargin-induced apoptosis (63, 75); few, however,
have been shown to affect Ca2 homeostasis following expo-
sure to thapsigargin. One of these, Bcl-2, shares intriguing
similarities with E3-6.7K, encompassing both their topology
and their posttranslational mode of targeting 39; A. R. Moise,
unpublished data) and possibly their putative mode of action.
Mitochondrion-localized Bcl-2 exerts its antiapoptotic effects
by blocking the release of cytochrome c from the mitochondria
(29). A subset of Bcl-2 proteins localizes to the cytoplasmic
face of the ER membrane (39). Both wild-type Bcl-2 and an
ER-restricted Bcl-2-cb5 fusion protein block the apoptotic
cross talk between the ER and the mitochondria (30), and
similarly to E3-6.7K, Bcl-2 has been shown to block thapsigar-
gin-induced Ca2 efflux from the ER (49). Recently, Bcl-2 was
shown to decrease the free Ca2 concentration within the ER
(24, 73) by increasing its permeability to Ca2, which results in
the depletion of the mobilizable Ca2 reserves used during
agonist- or apoptosis-induced efflux. It is possible that the
mechanism of E3-6.7K is related to the current model of the
mechanism of action of ER localized Bcl-2. In this case, ex-
pression of E3-6.7K should be able to induce a Ca2 “leak” in
the ER membrane, draining the mobilizable Ca2 reserves. It
could achieve this by regulating an existing channel or by
forming a channel of its own.
The effect of E3-6.7K on thapsigargin-induced Ca2 flux
places it upstream of many apoptotic effectors that are acti-
vated by of Ca2 release from the ER. Some of these effectors
are the death-associated protein kinase (14), protein kinase C
(98), the MEF2 transcription factor (105), and calcineurin.
Calcineurin, a Ca2-regulated serine-threonine phosphatase,
has been implicated in a variety of processes that result in the
induction of apoptosis by activating nuclear factor of activated
T-cells, which results in the expression of FasL (50), or by
activating the proapoptotic Bcl-2 family member Bad (100).
Recently, Ca2-induced proteases, such as the calpain class of
calcium-regulated cysteine proteases (74) and caspase-12, have
been implicated in apoptosis. The recently discovered
caspase-12 is activated by inducers of the ER stress response
and by calpains (65) but not by other inducers of apoptosis,
such as TNF (66).
Recently, the luminal environment of the ER and, more
particularly, ER chaperones has been shown to play an impor-
tant role in determining the sensitivity of cells to apoptosis
(67). Several ER-resident chaperone proteins, such as calreti-
culin (10) and BiP/Grp78 (57), appear to increase the Ca2
storage capacity of the ER (55, 67) and may regulate capaci-
tative Ca2 entry (64). Chaperone induction has also been
associated with viral infection, as many viruses induce an ER
overload response through the abundant expression of se-
creted viral proteins, as in the case of E3-6.7K’s cocistronic
partner E3/19K (71). The link between viral infection, ER
stress, and sensitivity to apoptosis is also hinted at by the
observation that both Gam1, an antiapoptotic protein encoded
by the avian adenovirus CELO (12, 26), and E1A (69) are
powerful inducers of heat shock proteins. In the case of Gam1,
this was an essential event for avian adenovirus replication. We
sought to examine whether the protective effect of E3-6.7K
observed in our study could be attributed to an effect on chap-
erone induction. We examined the expression of Grp94 and
Grp78 in transfected cells before and after induction with
thapsigargin or heat shock. Our results (not shown) indicated
that the presence of E3-6.7K did not affect the induction of
these two chaperones. We are currently examining the effect of
E3-6.7K on other markers of the stress response, such as c-Jun
NH2-terminal kinase, calpains, Hsp70, and caspase-12.
Future studies aimed at determining the mode of action of
ER localized pro-and antiapoptotic proteins will bridge the gap
between the ER stress response and apoptosis. We propose
that like E3-6.7K, other ER-localized viral survival factors are
good candidates for the functional dissection of these common
pathways.
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